Enhancing insulin sensitivity in type 2 diabetes mellitus using apelin-loaded small extracellular vesicles from Wharton’s jelly-derived mesenchymal stem cells: a novel therapeutic approach

Cui, Jing; Wang, Mingkun; Zhang, Wenhong; Sun, Jiachen; Zhang, Yan; Zhao, Li; Hong, Zhibo; Li, Dongtao; Huang, Yi Xiong; Zhang, Ningkun; Chen, Yu

doi:10.1186/s13098-024-01332-w

Fig. 4

From: Enhancing insulin sensitivity in type 2 diabetes mellitus using apelin-loaded small extracellular vesicles from Wharton’s jelly-derived mesenchymal stem cells: a novel therapeutic approach

Therapeutic efficacy of sEV treatment in T2DM mouse model. (a) Timeline of mouse treatment and research. (b) Changes in body weights of mice over time. (c) Blood glucose levels post-intravenous injection of MSC-sEVs and Ap-MSC-sEVs, or PBS as control; a significant reduction was observed in glucose levels, particularly with Ap-MSC-sEVs. (d–e) OGTT and IPITT results indicating improved glucose homeostasis in sEV-treated mice, with AP-MSC-sEVs showing increased efficacy compared to that of MSC-sEVs (*P < 0.05, **P < 0.01, ***P < 0.001). Abbreviations: sEVs, small extracellular vesicles; AP-MSC-sEVs, apelin-MSC-sEVs, engineered sEVs loaded with overexpressed apelin; Wharton’s jelly-derived mesenchymal stem cells (WJ-MSCs)

Back to article page

Fig. 4

Diabetology & Metabolic Syndrome

Contact us